Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?

Acquisition Details:
Novo Holdings is set to acquire Catalent in a $16.5 billion deal, which is expected to be finalized by the end of 2024.

Revenue Boost:
Catalent has seen a significant increase in revenue for the first time in over a year, ahead of the acquisition.

Impact on Catalent:
The acquisition will change Catalent from a publicly-traded company to a privately-owned entity, with potential implications for its local operations and employees.

Novo Holdings' Motivation:
The acquisition is likely driven by Novo Nordisk's need to expand production of its semaglutide drugs, Ozempic and Wegovy, which have seen a surge in demand.

Regulatory Review:
Novo Holdings has resubmitted its application to the Federal Trade Commission (FTC) to give the agency more time to review the deal.